Document:

Exhibit
10.11

 

THIS INSTRUMENT
AND ANY SECURITIES ISSUABLE PURSUANT HERETO HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED
OR HYPOTHECATED EXCEPT AS PERMITTED IN THIS INSTRUMENT AND UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT OR AN EXEMPTION THEREFROM.

 

 

NOCIMED, INC. SAFE

(Simple Agreement for Future
Equity)

 

THIS CERTIFIES
THAT in connection with entering into that certain Amended and Restated Commission Agreement on or about the date hereof, Nocimed, Inc.,
a Delaware corporation (the “Company”), hereby issues to NuVasive, Inc., a Delaware corporation (the “Investor”),
the right to certain shares of the Company’s capital stock, subject to the terms set forth below, in the amount of $2,000,000 (the
“Purchase Amount”) on February 28, 2020.

 

		1.	Basic Terms

 

(a)       
Tax Treatment. For income tax purposes, the Company and the Investor agree to treat this Safe as equity in
the Company and not indebtedness.

 

(b)       
No On-Demand Return of Purchase Amount. The Investor acknowledges that the Investor may not demand that the
Purchase Amount be repaid in cash to the Investor, and the Investor’s sole and exclusive rights under this Safe shall be to receive
the equity securities issuable upon conversion of this Safe pursuant to Section 2 of this Safe and any proceeds thereof or to receive
cash payments only in accordance with the specific events described in Section 2.

 

		2.	Events

 

(a)   
Equity Financing by December 31, 2020. If there is an Equity Financing on or before December 31, 2020, and before
the expiration or termination of this instrument, the Company will automatically issue to the Investor a number of shares of Safe Preferred
Stock equal to the Purchase Amount divided by the Conversion Price. In connection with the issuance of Safe Preferred Stock by the Company
to the Investor pursuant to this Section 2(a), the Investor will execute and deliver to the Company all transaction documents related
to the Equity Financing; provided, that such documents are the same documents to be entered into with the purchasers of Standard
Preferred Stock, with appropriate variations for the Safe Preferred Stock if applicable.

 

(b)   
No Equity Financing on or before December 31, 2020. If there is not an Equity Financing on or before December 31,
2020, and before the expiration or termination of this instrument, the Company will automatically issue to the Investor a number of shares
of Safe Series B-1 Plus Preferred Stock equal to the Purchase Amount divided by the price per share of the Company’s Series B-1
Preferred Stock of $1.2621 per share (the “Series B-1 Price”). In connection with the issuance of Safe Series B-1 Plus
Preferred Stock by the Company to the Investor pursuant to this Section 2(b), the Investor will execute and deliver to the Company the
documents executed in connection with the Company’s Series B-1 Preferred Stock financing, with appropriate variations for the Safe
Series B-1 Plus Preferred Stock if applicable.

 

 

 

    	 	1	 

     

    

 

(c) Change of Control. If there
is a Change of Control before the expiration or termination of this instrument, the Investor will, at the Investor’s option, either
(i) receive a cash payment equal to the Purchase Amount (subject to the following paragraph) or (ii) automatically receive from the Company
a number of shares of Common Stock equal to the Purchase Amount divided by the Series B-1 Price. In connection with Section (c)(i), the
Purchase Amount will be due and payable by the Company to the Investor immediately prior to, or concurrent with, the consummation of
the Change of Control. In connection with a Change of Control intended to qualify as a tax-free reorganization, the Company may reduce
the Purchase Amount payable to the Investor by the amount determined by its board of directors in good faith to be advisable for such
Change of Control to qualify as a tax-free reorganization for U.S. federal income tax purposes, and in such case, the Investor will automatically
receive the number of shares of Common Stock equal to the remaining unpaid Purchase Amount divided by the Discount Price. If paid in
cash, the Purchase Amount will be paid prior to any distributions to the holders of the Company’s Series B Preferred Stock and
Series B-1 Preferred Stock pursuant to the Company Charter.

 

(d)   
Dissolution Event. If there is a Dissolution Event before this instrument expires or terminates, the Company will
pay an amount equal to the Purchase Amount, due and payable to the Investor immediately prior to, or concurrent with, the consummation
of the Dissolution Event. The Purchase Amount will be paid prior to any distributions to the holders of the Company’s Series B Preferred
Stock and Series B-1 Preferred Stock pursuant to the Company Charter.

 

(e)   
Termination. This instrument will expire and terminate (without relieving the Company of any obligations arising
from a prior breach of or non-compliance with this instrument) upon the issuance of stock to the Investor pursuant to Section 1(a), Section
1(b) or Section 1(c)(ii), or the payment, or setting aside for payment, of amounts due to the Investor pursuant to Section 1(c)(i) or
Section 1(d).

 

		3.	Definitions

 

“Capital
Stock” means the capital stock of the Company, including, without limitation, the “Common Stock” and the
“Preferred Stock.”

 

“Change
of Control” means (i) a sale of all or substantially all of the Company’s assets other than to an Excluded Entity (as
defined below), (ii) a merger, consolidation or other capital reorganization or business combination transaction of the Company with or
into another corporation, limited liability company or other entity other than an Excluded Entity, or (iii) the consummation of a transaction,
or series of related transactions, in which any “person” (as such term is used in Sections 13(d) and 14(d) of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”)) becomes the “beneficial owner” (as defined in Rule
13d-3 of the Exchange Act), directly or indirectly, of all of the Company’s then outstanding voting securities. Notwithstanding
the foregoing, a transaction shall not constitute a Change of Control if its purpose is to (A) change the jurisdiction of the Company’s
incorporation, (B) create a holding company that will be owned in substantially the same proportions by the persons who hold the Company’s
securities immediately before such transaction, or (C) obtain funding for the Company in a financing that is approved by the Company’s
Board of Directors. An “Excluded Entity” means a corporation or other entity of which the holders of voting capital
stock of the Company outstanding immediately prior to such transaction are the direct or indirect holders of voting securities representing
at least a majority of the votes entitled to be cast by all of such corporation’s or other entity’s voting securities outstanding
immediately after such transaction.

 

“Conversion
Price” means the price per share paid by the investors investing new money into the Company in the Next Equity Financing.

 

“Dissolution
Event” means (i) a voluntary termination of operations, (ii) a general assignment for the benefit of the Company’s creditors
or (iii) any other liquidation, dissolution or winding up of the Company (excluding a Change of Control), whether voluntary or involuntary.

 

“Equity
Financing” means the Company’s next sale of capital stock in a single transaction or a series of related transactions
yielding gross proceeds to the Company of at least $10,000,000 (including conversion of outstanding convertible notes, this safe, and
any other safes or equity certificates).

 

“Safe”
means an instrument containing a future right to shares of Capital Stock, similar in form and content to this instrument, purchased by
investors for the purpose of funding the Company’s business operations.

 

 

    	 	2	 

     

    

 

“Safe
Preferred Stock” means the shares of a series of Preferred Stock issued to the Investor in an Equity Financing, having the identical
rights, privileges, preferences and restrictions as the shares of Standard Preferred Stock, other than with respect to: the right to appoint
a director to serve on the Company’s board of directors.

 

“Safe
Series B-1 Plus Preferred Stock” means the shares of a series of Preferred Stock issued to the Investor, having the identical
rights, privileges, preferences and restrictions as the shares of the Company’s Series B-1 Preferred Stock, other than with respect
to priority of payment in the event of a Liquidation Event (as defined in the Company Charter), which priority shall instead be the same
as the most senior series of Preferred Stock issued or to be issued at the time the Safe Series B-1 Plus Preferred Stock is issued (including
the Maturity Conversion Preferred (as defined in the 2020 Notes (as defined below))).

 

“Standard
Preferred Stock” means the shares of a series of Preferred Stock issued to the investors investing new money in the Company
in connection with the initial closing of the Equity Financing.

 

		4.	Company Representations

 

(a)   
The Company is a corporation duly organized, validly existing and in good standing under the laws of the state of its incorporation,
and has the power and authority to own, lease and operate its properties and carry on its business as now conducted.

 

(b)   
The execution, delivery and performance by the Company of this instrument is within the power of the Company and, other than with
respect to the actions to be taken for the authorization of Capital Stock issuable pursuant to Section 2, has been duly authorized by
all necessary actions on the part of the Company. This instrument constitutes a legal, valid and binding obligation of the Company, enforceable
against the Company in accordance with its terms, except as limited by bankruptcy, insolvency or other laws of general application relating
to or affecting the enforcement of creditors’ rights generally and general principles of equity. To the knowledge of the Company,
it is not in violation of (i) the Company Charter or bylaws, (ii) any material statute, rule or regulation applicable to the Company or
(iii) any material debt, indenture or contract to which the Company is a party or by which it is bound, where, in each case, such violation
or default, individually, or together with all such violations or defaults, could reasonably be expected to have a material adverse effect
on the Company.

 

(c)   
The performance and consummation of the transactions contemplated by this instrument do not and will not: (i) violate any material
judgment, statute, rule or regulation applicable to the Company; (ii) result in the acceleration of any material debt, indenture or contract
to which the Company is a party or by which it is bound; or (iii) result in the creation or imposition of any lien upon any property,
asset or revenue of the Company or the suspension, forfeiture, or nonrenewal of any material permit, license or authorization applicable
to the Company, its business or operations.

 

(d)   
No consents or approvals are required in connection with the performance of this instrument, other than: (i) the Company’s
corporate approvals; (ii) any qualifications or filings under applicable securities laws; and (iii) necessary corporate approvals for
the authorization of Capital Stock issuable pursuant to Section 2.

 

		5.	Investor Representations and Covenants

 

(a)   
The Investor has full legal capacity, power and authority to execute and deliver this instrument and to perform its obligations
hereunder. This instrument constitutes valid and binding obligation of the Investor, enforceable in accordance with its terms, except
as limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors’
rights generally and general principles of equity.

 

(b)   
The Investor is an accredited investor as such term is defined in Rule 501 of Regulation D under the Securities Act. The Investor
has been advised that this instrument and the underlying securities have not been registered under the Securities Act, or any state securities
laws and, therefore, cannot be resold unless they are registered under the Securities Act and applicable state securities laws or unless
an exemption from such registration requirements is available. The Investor is purchasing this instrument and the securities to be acquired
by the Investor hereunder for its own account for investment, not as a nominee or agent, and not with a view to, or for resale in connection
with, the distribution thereof, and the Investor has no present intention of selling, granting any participation in, or otherwise distributing
the same. The Investor has such knowledge and experience in financial and business matters that the Investor is capable of evaluating
the merits and risks of such investment, is able to incur a complete loss of such investment without impairing the Investor’s financial
condition and is able to bear the economic risk of such investment for an indefinite period of time.

 

 

    	 	3	 

     

    

 

(c)   
The Investor acknowledges and agrees that this instrument is junior in right of payment to the rights of payment of the holders
of the Company’s promissory notes issued as of the date hereof and issued after the date hereof, including but not limited to the
convertible notes issued pursuant to the Subordinated Convertible Promissory Note and Warrant Purchase Agreement entered into on or about
the date hereof (the “2020 Notes”), subject to Section 2(b) in the event this instrument converts into Safe Series
B-1 Plus Preferred Stock.

 

		6.	Miscellaneous

 

(a)   
Any provision of this instrument may be amended, waived or modified only upon the written consent of the Company and the Investor.

 

(b)   
Any notice required or permitted by this instrument will be deemed sufficient when delivered personally or by overnight courier
or sent by email to the relevant address listed on the signature page, or 48 hours after being deposited in the U.S. mail as certified
or registered mail with postage prepaid, addressed to the party to be notified at such party’s address listed on the signature page,
as subsequently modified by written notice.

 

(c)   
The Investor is not entitled, as a holder of this instrument, to vote or receive dividends or be deemed the holder of Capital Stock
for any purpose, nor will anything contained herein be construed to confer on the Investor, as such, any of the rights of a stockholder
of the Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof,
or to give or withhold consent to any corporate action or to receive notice of meetings, or to receive subscription rights or otherwise
until shares have been issued upon the terms described herein.

 

(d)   
Neither this instrument nor the rights contained herein may be assigned, by operation of law or otherwise, by either party without
the prior written consent of the other; provided, however, that this instrument and/or the rights contained herein may be assigned
without the Company’s consent by the Investor to any other entity who directly or indirectly, controls, is controlled by or is under
common control with the Investor, including, without limitation, any general partner, managing member, officer or director of the Investor,
or any venture capital fund now or hereafter existing which is controlled by one or more general partners or managing members of, or shares
the same management company with, the Investor; and provided, further, that the Company may assign this instrument in whole, without
the consent of the Investor, in connection with a reincorporation to change the Company’s domicile.

 

(e)   
In the event any one or more of the provisions of this instrument is for any reason held to be invalid, illegal or unenforceable,
in whole or in part or in any respect, or in the event that any one or more of the provisions of this instrument operate or would prospectively
operate to invalidate this instrument, then and in any such event, such provision(s) only will be deemed null and void and will not affect
any other provision of this instrument and the remaining provisions of this instrument will remain operative and in full force and effect
and will not be affected, prejudiced, or disturbed thereby.

 

(f)    
All rights and obligations hereunder will be governed by the laws of the State of California, without regard to the conflicts of
law provisions of such jurisdiction.

 

(g)  
The Company and the Investor hereby agree and acknowledge that the “Consolidation Limitation” provision in Section
3.13 of the that certain Amended and Restated Investors Rights Agreement dated as of July 27, 2017, by and among the Company and the investors
thereto, shall apply to any equity securities to be issued pursuant to this instrument.

 

 

(Signature
page follows)

 

 

    	 	4	 

     

    

 

 

IN WITNESS WHEREOF, the undersigned
have caused this instrument to be duly executed and delivered.

 

NOCIMED, INC.

 

By:                                                                        

L. Brett Lanuti

Chief Executive Officer

 

Address:

951 Mariners Island Blvd, Suite 300

San Mateo, California
94404

 

 

INVESTOR:

 

NUVASIVE,
INC.

 

By: ____________________________

Name:

Title:

 

Address:

 

7475 Lusk
Boulevard

San Diego, CA 92121

 

Email: _________________

 

 

 

 

 

SIGNATURE PAGE TO THE 2020 SAFE (NUVASIVE)

 

 

    	 	 	 

     

    

 

IN WITNESS WHEREOF, the undersigned
have caused this instrument to be duly executed and delivered.

 

NOCIMED, INC.

 

By:                                                                        

L. Brett Lanuti

Chief Executive Officer

 

Address:

951 Mariners Island Blvd, Suite 300

San Mateo, California
94404

 

 

INVESTOR:

 

NUVASIVE,
INC.

 

By: /s/
Sean Freeman                                         

Name:
Sean Freeman

Title:
SVP Strategy & Corporate Development

 

Address:

 

7475 Lusk
Boulevard

San Diego, CA 92121

 

 

 

 

 

SIGNATURE PAGE TO THE 2020 SAFE (NUVASIVE)Exhibit 10.12

 

CERTAIN IDENTIFIED INFORMATION
HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED, AND HAS
BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS HAVE BEEN MADE.

 

Execution Version

 

RIGHT OF FIRST OFFER AGREEMENT

 

THIS RIGHT
OF FIRST OFFER AGREEMENT (this “Agreement”) is effective as of February 18, 2015 (the “Effective
Date”) by and between NOCIMED, INC., a Delaware corporation with its principal place of business at 370 Convention
Way, Redwood City, CA 94063 (the “Company”), and NUVASIVE, INC., a Delaware corporation with its principal
place of business at 7475 Lusk Boulevard, San Diego, CA 92121 (“NuVasive”).

 

		1.	DEFINED TERMS

 

1.1  
“Affiliate” means, with respect to any Person, any other Person that directly or indirectly controls,
is controlled by or is under direct or indirect common control with, such Person. For purposes of this Section 1.1, the term “control”
means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether
through the ownership of voting securities, by contract or otherwise. Control of any Person by another Person shall be presumed if fifty
percent (50%) or more of the securities or other ownership interests representing the equity, the voting stock or general partnership
interest of such first Person are owned, controlled or held, directly or indirectly, by the other Person, or by an Affiliate of the other
Person.

 

		1.2	“Group Company” means the Company or any of its Affiliates.

 

1.3    
“Person” means any individual, corporation, partnership, trust, limited liability company, association
or other entity.

 

1.4  
“Restrictive Period” shall mean the period commencing on the Effective Date and ending on the date
that is three years after the first regulatory clearance issued by the United States Food and Drug Administration of a product or service
of the Company.

 

		2.	RIGHT OF FIRST OFFER

 

2.1  
The Company shall notify NuVasive within [***] days of the occurrence of either of the following: (i) a decision by any Group
Company to engage in discussions with any third party following any member of the Group Company’s receipt of any bona fide offer
or proposal to engage in a potential Sale Event (as defined in the Company’s Certificate of Incorporation as of the date hereof,
as may be amended from time-to-time) with any Group Company, or (ii) a decision by any Group Company to solicit from one or more third
parties offers or proposals for, or otherwise to commence discussions with a third party with respect to, a potential Sale Event.

 

2.2  
Prior to commencing or engaging in any discussions or negotiations with any third party regarding any potential Sale Event,
(i) the Company must first deliver to NuVasive a notice (the “ROFO Notice”) of the contemplated Sale Event,
which notice includes a detailed summary of all material terms on which the Sale Event is proposed (including, without limitation: (A)
the price; (B) whether any contingent consideration is proposed (e.g., milestones/earn-outs), and, if so, what the specific timelines
and goal lines (e.g., technical or sales-based? in either case, what constitutes milestone achievement?) are for achieving such contingent
consideration; (C) the make-up of the consideration (e.g., cash, cash/freely tradable security mix); (D) the methodology and assumption
supporting the proposed purchase price; (E) a basic summary of the indemnification terms offered to the proposed acquirer (e.g.,
is there an escrow? is there offsetting against milestones, if any? are there any special indemnification terms?); and (F) any other material
terms or conditions of the proposed transaction; and (ii) NuVasive shall have the right to engage in the Sale Event (the “ROFO”)
on the same terms provided in the ROFO Notice. Neither the Company nor any other Group Company shall enter into any Sale Event with a
third party or enter into any agreement(s) with any third party regarding any Sale Event, except in compliance with this Section 2.

 

 

    	 	1	 

     

    

 

2.3  
Following NuVasive’s receipt of a ROFO Notice, (i) upon request by NuVasive, the Company shall facilitate a due diligence
review by NuVasive, and (ii) NuVasive shall have [***] days from receipt of the ROFO Notice (the “ROFO Exercise Period”)
to respond to the ROFO Notice. Until the ROFO Exercise Period has passed (including, for the sake of clarity, at any time prior to the
Company’s delivery of the ROFO Notice), and/or NuVasive has responded in writing declining to engage in the proposed Sale Event
on the terms specified in the ROFO Notice, the Company may not engage in any discussions and/or enter into any written agreement(s) with
any third party regarding any Sale Event. Notwithstanding anything to the contrary contained herein, neither NuVasive nor the Company
shall be under any affirmative obligation to engage in the Sale Event.

 

2.4  
In the event NuVasive chooses to engage in the Sale Event on the terms specified in the ROFO Notice, NuVasive shall provide
written notice thereof to the Company during the ROFO Exercise Period (the “Exercise Notice”). Following receipt
of the Exercise Notice, the Company (or any other Group Company, as applicable) and NuVasive shall negotiate exclusively, expeditiously
and in good faith to execute definitive agreements to consummate a Sale Event on the terms set forth in the ROFO Notice. The parties shall
use commercially reasonable efforts to execute such definitive agreements within [***] days after receipt by Company of the Exercise Notice.

 

2.5  
In the event that NuVasive does not provide an Exercise Notice within the ROFO Exercise Period with respect to a proposed Sale
Event as described in Section 2.4, and/or NuVasive provides such an Exercise Notice within the ROFO Exercise Period but subsequently provides
written notice to the Company declining to engage in the Sale Event on the terms specified in the ROFO Notice (which subsequent written
notice NuVasive agrees to provide to the Company promptly following any good faith determination by NuVasive that it will not engage in
the Sale Event on the terms specified in the ROFO Notice), and only from and after such event, the Company shall have the right to engage
in negotiations and enter into definitive agreements with third parties regarding (including consummating) the proposed Sale Event. If,
however, during any such negotiations with a third party, the terms of the proposed Sale Event materially change (individually or in the
aggregate) from those that were previously presented to NuVasive in the ROFO Notice (“Amended Terms”), then,
prior to the Company consummating a Sale Event with such third party on such Amended Terms, the Company shall be required to first submit
a detailed proposal of such Amended Terms (the “Amended ROFO Notice”) to NuVasive and NuVasive shall have [***]
days to determine if it wishes to proceed with the Sale Event on the terms set forth in the Amended ROFO Notice, in which case the procedures
set forth in Sections 2.3 and 2.4 (and this Section 2.5) shall apply again with respect to such proposed Sale Event under the Amended
Terms (except that the relevant ROFO Exercise Period shall be halved). For purposes of the preceding sentence, a change in the terms of
the proposed Sale Event during any such negotiations with a third party shall not (by itself) be deemed a material change in the
terms of the proposed Sale Event so as to require an Amended ROFO Notice if it consists solely of an increase in the purchase price for
the proposed Sale Event.

 

2.6   The rights established by this Section
2 shall apply until the end of the Restrictive Period.

 

		3.	GENERAL

 

3.1  
Amendment and Waiver. This Agreement may be amended or modified only upon the written consent of the Company and NuVasive.

 

3.2   Assignment. Neither party may assign or transfer, by operation of law or otherwise, any of its rights, or delegate any of its
obligations, under this Agreement to any third party without the other party’s prior, written consent; provided, however,
that NuVasive may assign its rights under this Agreement to an assignee or transferee in a NuVasive Disposition (as defined in the Investor
Rights Agreement dated January , 2015). Any attempted assignment or transfer in violation of the foregoing will be null and void.

 

3.3   Notices. All notices, consents and approvals under this Agreement must be delivered in writing by courier, by electronic mail,
or by certified or registered mail (postage prepaid and return receipt requested) to the other party at the address set forth beneath
such party’s signature, and will be effective upon receipt or five (5) business days after being deposited in the mail as required
above, whichever occurs sooner. Either party may change its address by giving notice of the new address to the other party.

 

3.4  Governing Law. This Agreement will be governed by the laws of the State of California, excluding its conflicts of laws principles.

 

3.5  Waivers. All waivers must be in writing, and any waiver or failure to enforce any provision of this Agreement on one occasion
will not be deemed a waiver of any other provision or of such provision on any other occasion.

 

 

    	 	2	 

     

    

 

3.6  Severability. If any provision of this Agreement is unenforceable, such provision will be changed and interpreted to accomplish
the objectives of such provision to the greatest extent possible under applicable law and the remaining provisions will continue in full
force and effect.

 

3.7   Construction. The headings of Sections of this Agreement are for convenience and are not to be used in interpreting this Agreement.
As used in this Agreement, the word “including” means “including but not limited to”.

 

3.8   Counterparts; Execution. This Agreement may be executed (including via electronic signature (.PDF format included)) in counterparts,
each of which will be considered an original, but all of which together will constitute the same instrument.

 

3.9 
Entire Agreement. This Agreement constitutes the entire agreement between the parties regarding the subject hereof and supersedes
all prior or contemporaneous agreements, understandings, and communication, whether written or oral. This Agreement may be amended only
by a written document signed by both parties. The terms on any purchase order or similar document submitted by NuVasive to the Company
will have no effect.

 

[Signature Page Follows]

 

 

    	 	3	 

     

    

 

 

IN WITNESS
WHEREOF, the parties have executed this RIGHT OF FIRST OFFER AGREEMENT as of the Effective Date. 

 

 

	NOCIMED, INC.	NuVASIVE, INC.
	 	 
	 	 
	By: /s/
James C. Peacock
III                                

	By:  /s/
Jason M. Hannon                                    
	Name: James
C. Peacock III	Name: Jason
M. Hannon
	Title: Chief
Executive Officer	Title: Executive
Vice President, General Counsel
	 	 
	Address for Notice:	Address for Notice:
	370 Convention
Way

Redwood City , CA 94063

Attn: Chief Executive Officer

Email: [***]

	7475 Lusk
Boulevard

San
Diego , CA 92121

Attn: Jason
M. Hannon, EVP & GC

Email: [**]

 

 

 

 

 

 

 

 

SIGNATURE PAGE TO RIGHT OF
FIRST OFFER AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]